Smith, Lillian <br/><br/>
The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.  [electronic resource] 

 -  Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques  2016 
 - 137-46 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1482-1826 
<br/><br/><label>Standard No.: </label>10.18433/J3J02P  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Enzyme Inhibitors--chemistry<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Hyperlipidemias--drug therapy<br/>PCSK9 Inhibitors<br/>Proprotein Convertase 9--metabolism